| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
B
degradation
1 Angiogenesis Research Center, 2 Division of Molecular Medicine, Beth Israel Deaconess Medical Center, 3 Angiogenesis Research Center, Dartmouth Medical School, Hanover, New Hampshire 03756
PR-39 inhibits proteasome-mediated I
B
degradation
and might protect against ischemia-reperfusion injury. We
studied PR-39, its truncated form PR-11, and a mutant PR-11AAA, which
lacks the ability to prevent IB degradation, in a rat heart
ischemia-reperfusion model. After 30 min of
ischemia and 24 h of reperfusion, cardiac function,
infarct size, neutrophil infiltration, and myeloperoxidase activity
were measured. Intramyocardial injection of 10 nmol/kg PR-39 or PR-11
at the time of reperfusion reduced infarct size by 65% and 57%,
respectively, which improved blood pressure, left ventricular systolic
pressure, and relaxation and contractility (±dP/dt)
compared with vehicle controls 24 h later. Neutrophil infiltration, myeloperoxidase activity, and the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule 1 were reduced. Thus PR-39 and PR-11 effectively inhibit myocardial ischemia-reperfusion injury in the rat in vivo. This effect is mediated by inhibition of IB degradation and subsequent
inhibition of nuclear factor-B-dependent adhesion molecules. The
active sequence is located in the first 11 amino acids, suggesting a potential for oligopeptide therapy as an adjunct to revascularization.
rat; reactive oxygen species
This article has been cited by other articles:
|
|
 |
|
  F. S. Machado, L. Esper, A. Dias, R. Madan, Y. Gu, D. Hildeman, C. N. Serhan, C. L. Karp, and J. Aliberti Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF6 J. Exp. Med., May 12, 2008; 205(5): 1077 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Moss, W. E. Stansfield, M. S. Willis, R.-H. Tang, and C. H. Selzman IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2248 - H2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. E. Stansfield, N. C. Moss, M. S. Willis, R. Tang, and C. H. Selzman Proteasome Inhibition Attenuates Infarct Size and Preserves Cardiac Function in a Murine Model of Myocardial Ischemia-Reperfusion Injury Ann. Thorac. Surg., July 1, 2007; 84(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Shenoy Seven-Transmembrane Receptors and Ubiquitination Circ. Res., April 27, 2007; 100(8): 1142 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Powell The ubiquitin-proteasome system in cardiac physiology and pathology Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H1 - H19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Zolk, C. Schenke, and A. Sarikas The ubiquitin-proteasome system: Focus on the heart Cardiovasc Res, June 1, 2006; 70(3): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hedhli, M. Pelat, and C. Depre Protein turnover in cardiac cell growth and survival Cardiovasc Res, November 1, 2005; 68(2): 186 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Khurana, Z. Zhuang, S. Bhardwaj, M. Murakami, E. De Muinck, S. Yla-Herttuala, N. Ferrara, J. F. Martin, I. Zachary, and M. Simons Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia Circulation, October 19, 2004; 110(16): 2436 - 2443. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
